All In Biotech

Drug Trial Radar · NCT05768529

Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Single-arm, Open and Multicenter Phase I/II Clinical Study to Evaluate the Safety and Efficacy of U16 Injection in the Treatment of Refractory/Recurrent B-cell Non-Hodgkin's Lymphoma (r/r B-NHL)

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 28, 2023

Primary completion

Dec 31, 2028

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Mar 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase I/II, single-arm, open-label clinical trial, and its primary objective of phase I and phase II is to evaluate the safety and efficacy of U16 Injection in the treatment of relapsed or refractory NHL,respectively.

Conditions

  • Relapsed or Refractory Non-Hodgkin's Lymphoma

Interventions

  • U16Drug

    A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Types, frequency and severity of adverse eventsTime frame: 24 months
  2. Overall Remission Rate (ORR)Time frame: 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.